Esomeprazole
Based on 3 publication(s) in Google Scholar
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.32%
- CAS 番号: 119141-88-7
- 分子式: C17H19N3O3S
- 分子量:345.42
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
MedChemExpress(MCE)の使用を引用している文献 Esomeprazole
More
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | IC50 |
14.8 μM
Compound: omeprazole
|
Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay
Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay
|
[PMID: 25513712] |
| HEK293 | EC50 |
14000 nM
Compound: 1a
|
Agonist activity at recombinant BRS-3 receptor expressed in baculovirus-transduced HEK293 cells assessed as intracellular calcium mobilization by FLIPR assay
Agonist activity at recombinant BRS-3 receptor expressed in baculovirus-transduced HEK293 cells assessed as intracellular calcium mobilization by FLIPR assay
|
[PMID: 18818070] |
| HEK-293T | IC50 |
25 μM
Compound: Omeprazole
|
Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis
Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis
|
[PMID: 28512024] |
| HUVEC | GI50 |
>100 μM
Compound: Esomeprazole
|
Cytotoxicity against HUVEC cells
Cytotoxicity against HUVEC cells
|
[PMID: 31923859] |
| K562 | GI50 |
>100 μM
Compound: Esomeprazole
|
Antiproliferative activity against human K562 cells harboring MLL1
Antiproliferative activity against human K562 cells harboring MLL1
|
[PMID: 31923859] |
| L02 | GI50 |
>100 μM
Compound: Esomeprazole
|
Cytotoxicity against human L02 cells
Cytotoxicity against human L02 cells
|
[PMID: 31923859] |
| MOLM-13 | GI50 |
32 μM
Compound: Esomeprazole
|
Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9
Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9
|
[PMID: 31923859] |
| MV4-11 | GI50 |
47.6 μM
Compound: Esomeprazole
|
Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4
Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4
|
[PMID: 31923859] |
| Vero C1008 | CC50 |
>40 μM
Compound: Omeprazole
|
Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)
Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)
|
10.1101/2020.04.03.023846 |
| Vero C1008 | EC50 |
17.06 μM
Compound: Omeprazole
|
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days
Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days
|
10.1101/2020.04.03.023846 |
Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-468 cells
-
Concentration:25 µM, 50 µM, 75 µM, 100 µM
-
Incubation Time:20 hours
-
Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
-
Dosage:30 mg/kg, 300 mg/kg
-
Administration:Oral gavage; daily; for 19 or 11 days
-
Result:Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
化学情報
-
CAS 番号 119141-88-7
-
性状 Solid
-
分子量 345.42
-
分子式 C17H19N3O3S
-
Color White to light brown
-
SMILES
O=[S@](C1=NC2=CC=C(OC)C=C2N1)CC3=NC=C(C)C(OC)=C3C
-
別名
(S)-Omeprazole; (-)-Omeprazole
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
-
Int Immunopharmacol
Inhibition of iron ion accumulation alleviates polystyrene nanoplastics-induced pulmonary fibroblast proliferation and activation. [Abstract]2025 Aug 13:164:115367. PMID: 40811949 -
溶剤 & 溶解度
DMSO : ≥ 100 mg/mL (289.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]
[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]
[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8950 mL | 14.4751 mL | 28.9503 mL | 72.3757 mL |
| 5 mM | 0.5790 mL | 2.8950 mL | 5.7901 mL | 14.4751 mL | |
| 10 mM | 0.2895 mL | 1.4475 mL | 2.8950 mL | 7.2376 mL | |
| 15 mM | 0.1930 mL | 0.9650 mL | 1.9300 mL | 4.8250 mL | |
| 20 mM | 0.1448 mL | 0.7238 mL | 1.4475 mL | 3.6188 mL | |
| 25 mM | 0.1158 mL | 0.5790 mL | 1.1580 mL | 2.8950 mL | |
| 30 mM | 0.0965 mL | 0.4825 mL | 0.9650 mL | 2.4125 mL | |
| 40 mM | 0.0724 mL | 0.3619 mL | 0.7238 mL | 1.8094 mL | |
| 50 mM | 0.0579 mL | 0.2895 mL | 0.5790 mL | 1.4475 mL | |
| 60 mM | 0.0483 mL | 0.2413 mL | 0.4825 mL | 1.2063 mL | |
| 80 mM | 0.0362 mL | 0.1809 mL | 0.3619 mL | 0.9047 mL | |
| 100 mM | 0.0290 mL | 0.1448 mL | 0.2895 mL | 0.7238 mL |